Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002211 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

A NA study of HIV Infections, sponsored by Pharmacia and Upjohn.

Completed
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT00002211: Completed NA study of HIV Infections, sponsored by Pharmacia and Upjohn.

NCT00002211 is a NA study of HIV Infections that has completed, run by Pharmacia and Upjohn. The registered enrollment target is 160 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002211, a NA study of HIV Infections, has completed, sponsored by Pharmacia and Upjohn.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).

Conditions Studied

HIV Infections

Interventions

  • DRUG Stavudine
  • DRUG Didanosine
  • DRUG Nelfinavir mesylate
  • DRUG Delavirdine mesylate

Study Locations (1)

New Jersey

  • Pharmacia & Upjohn - Peapack

Trial Details

FieldValue
Enrollment Target 160 participants
Phase NA

Sponsor

Pharmacia and Upjohn

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002211

The ClinicalTrials.gov registry entry for NCT00002211 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (64% lower). The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Stavudine is the first listed.

NCT00002211 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002211 about?

NCT00002211 is a clinical study titled "Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).

What is the current status of trial NCT00002211?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants.

What conditions does trial NCT00002211 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002211?

The interventions under investigation include: Stavudine (DRUG), Didanosine (DRUG), Nelfinavir mesylate (DRUG), Delavirdine mesylate (DRUG).

Who is sponsoring clinical trial NCT00002211?

This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002211 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.